PEA-15 (phospho Ser116) Polyclonal Antibody

    • Catalog No.:YP0669
    • Applications:WB;IHC;IF;ELISA
    • Reactivity:Human;Mouse;Rat;Monkey
      • Target:
      • PEA-15
      • Gene Name:
      • PEA15
      • Protein Name:
      • Astrocytic phosphoprotein PEA-15
      • Human Gene Id:
      • 8682
      • Human Swiss Prot No:
      • Q15121
      • Mouse Swiss Prot No:
      • Q62048
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human PEA-15 around the phosphorylation site of Ser116. AA range:81-130
      • Specificity:
      • Phospho-PEA-15 (S116) Polyclonal Antibody detects endogenous levels of PEA-15 protein only when phosphorylated at S116.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:5000.. IF 1:50-200
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • PEA15;Astrocytic phosphoprotein PEA-15;15 kDa phosphoprotein enriched in astrocytes;Phosphoprotein enriched in diabetes;PED
      • Observed Band(KD):
      • 15kD
      • Background:
      • phosphoprotein enriched in astrocytes 15(PEA15) Homo sapiens This gene encodes a death effector domain-containing protein that functions as a negative regulator of apoptosis. The encoded protein is an endogenous substrate for protein kinase C. This protein is also overexpressed in type 2 diabetes mellitus, where it may contribute to insulin resistance in glucose uptake. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014],
      • Function:
      • function:Blocks Ras-mediated inhibition of integrin activation and modulates the ERK MAP kinase cascade. Inhibits RPS6KA3 activities by retaining it in the cytoplasm (By similarity). Inhibits both TNFRSF6- and TNFRSF1A-mediated CASP8 activity and apoptosis. Regulates glucose transport by controlling both the content of SLC2A1 glucose transporters on the plasma membrane and the insulin-dependent trafficking of SLC2A4 from the cell interior to the surface.,PTM:Phosphorylated by protein kinase C and calcium-calmodulin-dependent protein kinase. These phosphorylation events are modulated by neurotransmitters or hormones.,similarity:Contains 1 DED (death effector) domain.,subcellular location:Associated with microtubules.,subunit:Binds RPS6KA3, MAPK3 and MAPK1. Transient interaction with PLD1 and PLD2 (By similarity). Interacts with CASP8 and FADD.,tissue specificity:Ubiquitously expressed. Mo
      • Subcellular Location:
      • Cytoplasm. Associated with microtubules.
      • Expression:
      • Ubiquitously expressed. Most abundant in tissues such as heart, brain, muscle and adipose tissue which utilize glucose as an energy source. Lower expression in glucose-producing tissues. Higher levels of expression are found in tissues from individuals with type 2 diabetes than in controls.
      • Products Images
      • Western blot analysis of COLO 3T3 using p-PEA-15 (S116) antibody. Antibody was diluted at 1:500
      • Immunohistochemistry analysis of paraffin-embedded human skeletal muscle, using PEA-15 (Phospho-Ser116) Antibody. The picture on the right is blocked with the phospho peptide.
      • Western blot analysis of lysates from COS7 cells treated with INSULIN 0.01U/ML 15', using PEA-15 (Phospho-Ser116) Antibody. The lane on the right is blocked with the phospho peptide.